Showing 51-60 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Low-dose IL-2 and anti-CD40L as a therapy for type 1 diabetes | University of Miami | Thomas Malek | Cures | 01-June-2024 to 31-May-2027 | $927,000.00 |
| Enhance β-Cell Replacement Therapies via Localized Immune Modulation Using DIANA Nanocarriers | University of Miami | Peter Buchwald | Cures | 01-September-2023 to 31-August-2026 | $900,000.00 |
| bifunctional RNA therapeutics for T1D | University of Miami | Paolo Serafini | Cures | 01-February-2025 to 31-January-2028 | $900,000.00 |
| Modulate beta cell proliferation and immunogenicity via aptamer-decorated lipid nanoparticles | University of Miami | Paolo Serafini | Cures | 01-April-2023 to 31-March-2026 | $894,602.00 |
| Role of pericytes during type 1 diabetes pathogenesis | University of Miami | Luciana Mateus Goncalves | Cures | 01-March-2024 to 28-February-2027 | $259,750.00 |
| Preclinical development of the BMP receptor agonist THR-184 for beta cell regeneration | University of Miami | Juan Dominguez-Bendala | Cures | 01-April-2024 to 31-March-2027 | $741,000.00 |
| Towards an integrated proteomic and transcriptomic single-cell atlas of the human pancreas | University of Miami | Dirk Homann | Cures | 01-April-2025 to 31-March-2026 | $53,972.92 |
| Localized delivery of costimulatory inhibitors and tolerogenic stromal cells for targeted immunomodulation in beta cell replacement | University of Miami | Alice Tomei | Cures | 01-February-2024 to 31-January-2027 | $750,000.00 |
| In vivo interactions and trafficking of islet antigen-specific human effector T cells and Tregs | University of Massachusetts Medical School | Michael Brehm | Cures | 01-November-2024 to 31-October-2027 | $825,000.00 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2022 to 30-September-2025 | $12,998,645.40 |